Who is Anne Wojcicki and what is TTAM Research Institute

Anne Wojcicki is the cofounder and former CEO of 23andMe TTAM Research Institute is a nonprofit she established which submitted the winning bid to acquire the companys assets

How much did TTAM offer to acquire 23andMe

TTAM submitted a 305 million bid surpassing a competing 256 million offer from Regeneron Pharmaceuticals

Does the deal include customer genetic data

The acquisition focuses on 23andMes assets not the sale of customer data TTAM is committed to maintaining strict privacy protections for genetic information

What liabilities are excluded from this acquisition

Liabilities linked to a 2023 data breach affecting millions of customers remain with the bankruptcy estate and are not part of TTAMs purchase

What impact will this acquisition have on 23andMes business

The acquisition could help 23andMe overcome recent financial challenges improve privacy standards and stabilize its market presence under new ownership

Anne Wojcicki’s Nonprofit Wins $305M Bid to Reclaim 23andMe

🔸Published: 14 Jun 2025 09:54 AM

🔸Updated: 14 Jun 2025 09:54 AM

Anne Wojcicki’s nonprofit outbids Regeneron with $305M to acquire 23andMe, aiming to improve privacy and steer the genetic testing company out of bankruptcy.

Anne Wojcicki, the co-founder and former CEO of the genetic testing giant 23andMe, has successfully reclaimed control of the company through a $305 million winning bid made by her nonprofit organization, TTAM Research Institute. This development comes in the wake of 23andMe’s Chapter 11 bankruptcy filing earlier this year, followed by an auction process aimed at resolving the company’s financial struggles.

More Articles:

The Auction Battle: TTAM Outbids Regeneron

The auction for 23andMe’s assets saw fierce competition, with biotech heavyweight Regeneron Pharmaceuticals initially putting forward a $256 million bid. However, TTAM Research Institute, led by Wojcicki herself, ultimately outbid Regeneron with a $305 million offer. The sale is now awaiting final approval from the bankruptcy court, with a hearing set for June 17.

TTAM has emphasized that maintaining and strengthening consumer privacy protections will be a top priority going forward, promising to uphold the company's existing privacy policies and implement additional safeguards to protect customer data.

What’s Included in the Deal?

TTAM’s acquisition covers nearly all of 23andMe’s assets, but it notably excludes certain liabilities. This includes the fallout from a 2023 data breach that compromised the information of approximately 7 million customers. Those liabilities will remain with the bankruptcy estate rather than transferring to TTAM.

The deal also aims to address ongoing privacy concerns expressed by several U.S. states about the handling and transfer of customer genetic data, signaling a renewed commitment to compliance and consumer trust.

Anne Wojcicki’s Nonprofit Wins 23andMe Bankruptcy Auction With $305 Million Bidhttps://t.co/UTImweeJlQ
— DeepNewz (@deepnewzcom) June 14, 2025

What This Means for 23andMe’s Future

If the sale gains court approval, it could mark the start of a new chapter for 23andMe. The company, which pioneered direct-to-consumer genetic testing, has faced mounting financial and legal pressures. Under TTAM’s stewardship, there is hope that 23andMe will stabilize its operations, improve its privacy practices, and rebuild consumer confidence in its services.

Disclaimer

This article is based on information available from public sources and is intended solely for informational purposes. Procapitas does not guarantee the completeness or accuracy of this report. Readers should seek advice from official filings and qualified financial professionals before making investment decisions.

Source

Bloomberg Article: 23andMe Co-Founder Wins Auction for Genetic Data.

Start Your Career Journey

Get hired in just one click